| Alectinib (Alecensa) | An oral kinase inhibitor for certain types of non–small-cell lung (NSCL) cancer. |
| Atezolizumab (Tecentriq) | A programmed death-ligand 1 (PD-L 1) blocking antibody for treatment of advanced urothelial carcinoma (bladder cancer) |
| Brivaracetam (Briviact) | A selective, high-affinity synaptic vesicle protein 2A ligand for treatment of partial onset seizures |
| Cabozantinib (Cabometyx) | A tyrosine kinase inhibitor for treatment of advanced renal cell carcinoma |
| Cobimetinib (Cotellic) | An oral kinase inhibitor for advanced melanoma |
| Daclizumab (Zinbryta) | An interleukin-2 receptor blocking antibody indicated for relapsing forms of multiple sclerosis |
| Daratumumab (Darzalex) | A monoclonal antibody for multiple myeloma |
| Elbasvir and grazoprevir (Zepatier) | Combination NS5A replication complex inhibitor and NS3/4A protease inhibitor for treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections. |
| Elotuzumab (Empliciti) | An immune system activator for multiple myeloma |
| Ikekizumab (Taltz) | A humanized interleukin-17A antagonist for treatment of adults with moderate to severe plaque psoriasis |
| Ixazombi (Ninlaro) | An oral proteasome inhibitor for multiple myeloma |
| Lixisenatide (Adylyxin) | A glucagon receptor agonist used as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes |
| Mepolizumab (Nucala) | A monoclonal antibody for add-on maintenance treatment of severe asthma |
| Necitumumab (Portrazza) | An epidermal growth factor receptor antagonist for metastatic squamous non–small-cell lung (NSCL) cancer |
| Osimertinib (Tagrisso) | An oral kinase inhibitor for metastatic non–small-cell lung (NSCL) cancer |
| Patiromer (Veltassa) | An oral potassium binder for hyperkalemia |
| Pimavanserin (Nuplazid) | An atypical antipsychotic for Parkinson’s disease psychosis |
| Reslizumab (Cinqair) | An interleukin-5 antagonist for add-on maintenance treatment of severe asthma |
| Sofosbuvir/velpatasvir (Epclusa) | Fixed-dose combination for treatment of chronic hepatitis C |
| Trabectedin (Yondelis) | An alkylating agent for advanced soft tissue sarcomas |
| Venetoclax (Venelexta) | A BCL-2 inhibitor for chronic lymphocytic leukemia |